NO20002957L - Behandling med anti-ErbB2-antistoffer - Google Patents

Behandling med anti-ErbB2-antistoffer

Info

Publication number: NO20002957L
Authority: NO; Norway
Prior art keywords: treatment; erbb2 antibodies; erbb2; antibodies
Prior art date: 1997-12-12

Application number

NO20002957A

Other languages

English (en)

Norwegian (no)

Other versions

NO20002957D0 (no

Inventor

Steven Shak

Virginia E Paton

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-12

Filing date

2000-06-09

Publication date

2000-08-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22088358&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20002957(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-09 Application filed by Genentech Inc filed Critical Genentech Inc

2000-06-09 Publication of NO20002957D0 publication Critical patent/NO20002957D0/no

2000-08-11 Publication of NO20002957L publication Critical patent/NO20002957L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

NO20002957A 1997-12-12 2000-06-09 Behandling med anti-ErbB2-antistoffer NO20002957L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6934697P	1997-12-12	1997-12-12
PCT/US1998/026266 WO1999031140A1 (fr)	1997-12-12	1998-12-10	TRAITEMENT AUX ANTICORPS ANTI-ErbB2

Publications (2)

Publication Number	Publication Date
NO20002957D0 NO20002957D0 (no)	2000-06-09
NO20002957L true NO20002957L (no)	2000-08-11

Family

ID=22088358

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20002957A NO20002957L (no)	1997-12-12	2000-06-09	Behandling med anti-ErbB2-antistoffer
NO20091147A NO20091147L (no)	1997-12-12	2009-03-17	Behandling med anti-ErbB2-antistoff

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20091147A NO20091147L (no)	1997-12-12	2009-03-17	Behandling med anti-ErbB2-antistoff

Country Status (17)

Country	Link
US (11)	US7846441B1 (fr)
EP (3)	EP2275450A1 (fr)
JP (7)	JP2002508397A (fr)
KR (7)	KR20010033019A (fr)
CN (2)	CN1269839C (fr)
AR (1)	AR020051A1 (fr)
AU (1)	AU1908199A (fr)
BR (1)	BR9815363A (fr)
CA (2)	CA2730373A1 (fr)
DK (1)	DK1037926T3 (fr)
ES (1)	ES2450922T3 (fr)
IL (4)	IL136201A0 (fr)
NO (2)	NO20002957L (fr)
NZ (1)	NZ504597A (fr)
TR (1)	TR200001689T2 (fr)
WO (1)	WO1999031140A1 (fr)
ZA (1)	ZA9811162B (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2697752B1 (fr)	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US6524832B1 (en)	1994-02-04	2003-02-25	Arch Development Corporation	DNA damaging agents in combination with tyrosine kinase inhibitors
US7371376B1 (en)	1996-10-18	2008-05-13	Genentech, Inc.	Anti-ErbB2 antibodies
US6972170B1 (en)	1997-12-01	2005-12-06	Sloan-Kettering Institute For Cancer Research	Markers for prostate cancer
ZA9811162B (en) *	1997-12-12	2000-06-07	Genentech Inc	Treatment with anti-ERBB2 antibodies.
US6417168B1 (en)	1998-03-04	2002-07-09	The Trustees Of The University Of Pennsylvania	Compositions and methods of treating tumors
US6333348B1 (en)	1999-04-09	2001-12-25	Aventis Pharma S.A.	Use of docetaxel for treating cancers
US6316462B1 (en)	1999-04-09	2001-11-13	Schering Corporation	Methods of inducing cancer cell death and tumor regression
SI1187632T1 (sl) *	1999-05-14	2009-04-30	Genentech Inc	Zdravljenje z anti-ErbB2 protitelesi
WO2000077258A1 (fr) *	1999-06-10	2000-12-21	Sloan-Kettering Institute For Cancer Research	Marqueurs du cancer de la prostate
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
US20040013667A1 (en) *	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
EP1189634B1 (fr) *	1999-06-25	2007-02-28	Genentech, Inc.	Traitement du cancer de la prostate a l'aide des anticorps anti-erbb2
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) *	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
GEP20104998B (en) *	1999-06-25	2010-06-10	Genentech Inc	Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
ES2662581T3 (es)	1999-06-25	2018-04-09	Immunogen, Inc.	Métodos de tratamiento usando conjugados de anticuerpo anti-ErbB-maitansinoide
AU779612C (en) *	1999-07-02	2005-12-15	Genentech Inc.	Peptide compounds that bind HER2
GB9917012D0 (en) *	1999-07-20	1999-09-22	Pharmacia & Upjohn Spa	Combined preparations comprising antitumor agents
DE69934259T2 (de)	1999-07-23	2007-05-31	Glaxo Group Ltd., Greenford	Kombination von einem Anti-Ep-CAM-Antikörper mit einem chemotherapeutischen Mittel
EP1246597B1 (fr) *	1999-08-03	2015-01-14	The Ohio State University	Polypeptides et polynucleotides ameliorant la reactivite immunitaire a la proteine her-2
DE60042693D1 (de) *	1999-08-27	2009-09-17	Genentech Inc	Dosierung für die behandlung mit anti erbb2-antikörpern
EP2289549A3 (fr)	1999-10-01	2011-06-15	Immunogen, Inc.	Des immunoconjugués pour le traitement des cancers.
CA2395832A1 (fr)	2000-01-25	2001-08-02	Genentech, Inc.	Compositions et methodes de traitement de cancer
US7097840B2 (en)	2000-03-16	2006-08-29	Genentech, Inc.	Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP1265635A1 (fr) *	2000-03-22	2002-12-18	Glaxo Group Limited	Produit pharmaceutique comprenant un agent bloquant le cycle cellulaire et anticorps
IL152389A0 (en) *	2000-05-15	2003-05-29	Pharmacia Italia Spa	Aromatase inhibitors and monoclonal anti-her1 antibodies as antitumor agents
NZ522444A (en) *	2000-05-19	2004-09-24	Genentech Inc	Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
GB0017635D0 (en) *	2000-07-18	2000-09-06	Pharmacia & Upjohn Spa	Antitumor combined therapy
WO2002087618A1 (fr) *	2001-04-27	2002-11-07	Takeda Chemical Industries, Ltd.	Methode de prevention et de traitement du cancer
WO2002087619A1 (fr) *	2001-04-27	2002-11-07	Takeda Chemical Industries, Ltd.	Methode de prevention et de traitement du cancer
EP1495055B1 (fr) *	2002-04-18	2013-08-14	Genencor International, Inc.	Production d'anticorps fonctionnels dans des champignons filamenteux
CA2487600C (fr) *	2002-05-30	2011-07-05	Toray Industries, Inc.	Adsorbants pour substance immunosuppressive, colonne de circulation extracorporelle, et procedes de traitement du cancer
AU2002951853A0 (en) *	2002-10-04	2002-10-24	Commonwealth Scientific And Industrial Research Organisation	Crystal structure of erbb2 and uses thereof
US8088387B2 (en)	2003-10-10	2012-01-03	Immunogen Inc.	Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GT200500155A (es) *	2004-06-16	2006-05-15		Terapia del càncer resistente al platino
HRP20141111T1 (hr)	2004-07-22	2015-01-02	Genentech, Inc.	Sastav her2-protutijela
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
KR20070085855A (ko) *	2004-12-07	2007-08-27	제넨테크, 인크.	Ｈｅｒ 억제제를 이용한 치료를 위한 환자 선택 방법
BRPI0518104B8 (pt)	2005-01-21	2021-05-25	Genentech Inc	artigo industrializado e uso de anticorpo her2
EP1846558A2 (fr) *	2005-02-09	2007-10-24	Genentech, Inc.	Inhibition d'excretion de her2 au moyen d'antagonistes de metalloprotease matricielle
RU2404806C2 (ru) *	2005-02-23	2010-11-27	Дженентек, Инк.	Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
TW200642695A (en) *	2005-03-08	2006-12-16	Genentech Inc	Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
JP2006316040A (ja)	2005-05-13	2006-11-24	Genentech Inc	Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
JP5222134B2 (ja)	2005-06-15	2013-06-26	ザオハイオステートユニバーシティーリサーチファウンデーション	Ｈｅｒ−２ペプチド
PE20070207A1 (es) *	2005-07-22	2007-03-09	Genentech Inc	Tratamiento combinado de los tumores que expresan el her
US20100168393A1 (en) *	2005-10-11	2010-07-01	Big Glucose Ltd.	Antibody Polypeptide Libray Screening and Selected Antibody Polypeptides
TW200812615A (en)	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
SI2056874T1 (sl)	2006-08-21	2012-12-31	F. Hoffmann-La Roche Ag	Terapija tumorjev s protitelesom proti vegf
CA2677108A1 (fr)	2007-03-02	2008-09-12	Genentech, Inc.	Element de prevision de la reponse a un inhibiteur de her
US8557588B2 (en) *	2007-03-27	2013-10-15	Schlumberger Technology Corporation	Methods and apparatus for sampling and diluting concentrated emulsions
US20090304590A1 (en) *	2007-05-29	2009-12-10	Wyeth	Therapeutic compositions and methods
WO2008150485A2 (fr) *	2007-05-29	2008-12-11	Wyeth	Compositions thérapeutiques et procédés
WO2008154249A2 (fr)	2007-06-08	2008-12-18	Genentech, Inc.	Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur her2
US9551033B2 (en)	2007-06-08	2017-01-24	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP3381445B1 (fr) *	2007-11-15	2023-10-25	Amgen Inc.	Formulation aqueuse d'anticorps stabilisée par des antioxydants pour administration parentérale
CA2711843C (fr)	2007-12-20	2018-11-13	Laboratory Corporation Of America Holdings	Procedes de diagnostic du her-2
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
ES2342646B1 (es) *	2008-06-02	2011-04-26	Institut De Recerca Hospital Universitari Vall Hebron	Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
BRPI0812682A2 (pt)	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
EP2362783A2 (fr) *	2008-10-31	2011-09-07	Biogen Idec MA Inc.	Molécules ciblant light et leurs utilisations
SG171780A1 (en)	2008-11-22	2011-07-28	Genentech Inc	Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
EP2438442B1 (fr)	2008-12-01	2017-08-09	Laboratory Corporation of America Holdings	Procédés et dosages pour mesurer p95 et/ou des complexes de p95 dans un échantillon et anticorps spécifiques de p95
SG172983A1 (en)	2009-01-15	2011-08-29	Lab Corp America Holdings	Methods of determining patient response by measurement of her-3
US20100234283A1 (en)	2009-02-04	2010-09-16	The Ohio State University Research Foundation	Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
EP2408817B1 (fr)	2009-03-20	2016-03-16	F.Hoffmann-La Roche Ag	Anticorps anti-her di-spécifiques
US20120121586A1 (en)	2009-05-29	2012-05-17	Astrid Kiermaier	Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
SG183333A1 (en)	2010-02-18	2012-09-27	Genentech Inc	Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (fr)	2010-05-19	2011-11-24	Genentech, Inc.	Prédiction de réponses à un inhibiteur de her
CN103153339B (zh)	2010-05-27	2021-05-04	根马布股份公司	针对her2表位的单克隆抗体
CA2800785C (fr)	2010-05-27	2019-09-24	Genmab A/S	Anticorps monoclonaux contre her2
JP5940061B2 (ja)	2010-06-18	2016-06-29	ジェネンテック，インコーポレイテッド	抗ａｘｌ抗体及び使用方法
TW201302793A (zh)	2010-09-03	2013-01-16	Glaxo Group Ltd	新穎之抗原結合蛋白
CN101974535B (zh) *	2010-11-03	2012-12-19	北京天广实生物技术股份有限公司	新型抗ErbB2人源化抗体MIL12的制备及其应用
EP2643353A1 (fr)	2010-11-24	2013-10-02	Novartis AG	Molécules multi-spécifiques
JP5766296B2 (ja)	2010-12-23	2015-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
JP2014514314A (ja)	2011-04-20	2014-06-19	ゲンマブエー／エス	Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
CA2842375A1 (fr)	2011-08-17	2013-02-21	Erica Jackson	Anticorps anti-neureguline et utilisations associees
RU2614254C2 (ru)	2011-08-31	2017-03-24	Дженентек, Инк.	Диагностические маркеры
PT4241849T (pt)	2011-10-14	2024-10-30	Hoffmann La Roche	Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
WO2013063229A1 (fr)	2011-10-25	2013-05-02	The Regents Of The University Of Michigan	Traitement par un agent de ciblage de her2 dans des cancers non amplifiés par her2 ayant des cellules souches cancéreuses exprimant her2
CA2857114A1 (fr)	2011-11-30	2013-06-06	Genentech, Inc.	Mutations dans erbb3 dans des cancers
EP2788500A1 (fr)	2011-12-09	2014-10-15	F.Hoffmann-La Roche Ag	Identification de non-répondeurs aux inhibiteurs de her2
CN104220457A (zh)	2012-03-27	2014-12-17	霍夫曼-拉罗奇有限公司	涉及her3抑制剂的诊断和治疗
EP2719706A1 (fr)	2012-10-15	2014-04-16	Universität Zürich	Ligands de HER2 bispécifiques pour la thérapie du cancer
JP2015532306A (ja)	2012-10-15	2015-11-09	チューリッヒ大学	癌治療のための二重特異性ｈｅｒ２リガンド
EP3511718A1 (fr)	2012-11-30	2019-07-17	F. Hoffmann-La Roche AG	Inhibiteur de pd-l1
AR095863A1 (es)	2013-04-16	2015-11-18	Genentech Inc	Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
KR20160003141A (ko)	2013-05-01	2016-01-08	파이브 프라임 테라퓨틱스, 인크.	암을 치료하는 방법
CA2946860A1 (fr)	2014-04-25	2015-10-29	Genentech, Inc.	Methodes de traitement du cancer du sein precoce avec du trastuzumab-mcc-dm1 et du pertuzumab
FI3302551T3 (fi)	2015-05-30	2024-08-27	Hoffmann La Roche	Menetelmiä her2-positiivisen, aiemmin hoitamattoman metastaattisen rintasyövän hoitamiseksi
WO2017087280A1 (fr)	2015-11-16	2017-05-26	Genentech, Inc.	Procédés de traitement d'un cancer positif her2
US20190151346A1 (en)	2016-05-10	2019-05-23	INSERM (Institute National de la Santé et de la Recherche Médicale)	Combinations therapies for the treatment of cancer
CN115317603A (zh) *	2016-07-07	2022-11-11	小利兰·斯坦福大学托管委员会	抗体佐剂缀合物
KR20190075114A (ko)	2016-11-04	2019-06-28	제넨테크, 인크.	Her2-양성 유방암의 치료
WO2018125589A1 (fr)	2016-12-28	2018-07-05	Genentech, Inc.	Traitement du cancer exprimant her2 avancé
SI3570884T1 (sl)	2017-01-17	2021-02-26	Genentech, Inc.	Subkutane formulacije protiteles HER2
CN114984206A (zh)	2017-03-02	2022-09-02	基因泰克公司	Her2阳性乳腺癌的辅助治疗
WO2018200505A1 (fr)	2017-04-24	2018-11-01	Genentech, Inc.	Mutations erbb2/her2 dans le domaine transmembranaire ou juxtamembranaire
JP2019043214A (ja)	2017-08-30	2019-03-22	いすゞ自動車株式会社	ステアリング装置
AU2019358419A1 (en)	2018-10-08	2021-04-15	Universität Zürich	HER2-binding tetrameric polypeptides
EP3937984A1 (fr)	2019-03-15	2022-01-19	Bolt Biotherapeutics, Inc.	Immunoconjugués ciblant le her2
KR20250151568A (ko)	2020-06-29	2025-10-21	제넨테크, 인크.	퍼투주맙 + 트라스투주맙 고정 용량 조합
IL303350A (en)	2020-12-04	2023-08-01	Macrogenics Inc	Pharmaceutical compositions of a her2/neu antibody and use of the same

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US444960A (en) *		1891-01-20		Fence or gate
US4017471A (en)	1975-09-15	1977-04-12	G. D. Searle & Co.	Immunological compounds
US4935341A (en)	1986-06-04	1990-06-19	Whitehead Institute For Biomedical Research	Detection of point mutations in neu genes
US6054561A (en)	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
US5169774A (en)	1984-02-08	1992-12-08	Cetus Oncology Corporation	Monoclonal anti-human breast cancer antibodies
US4753894A (en)	1984-02-08	1988-06-28	Cetus Corporation	Monoclonal anti-human breast cancer antibodies
US4943533A (en)	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US7838216B1 (en)	1986-03-05	2010-11-23	The United States Of America, As Represented By The Department Of Health And Human Services	Human gene related to but distinct from EGF receptor gene
US5401638A (en)	1986-06-04	1995-03-28	Oncogene Science, Inc.	Detection and quantification of neu related proteins in the biological fluids of humans
US4994558A (en)	1986-12-24	1991-02-19	Eli Lilly And Company	Immunoglobulin conjugates
US4968603A (en)	1986-12-31	1990-11-06	The Regents Of The University Of California	Determination of status in neoplastic disease
US4975278A (en)	1988-02-26	1990-12-04	Bristol-Myers Company	Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5824311A (en)	1987-11-30	1998-10-20	Trustees Of The University Of Pennsylvania	Treatment of tumors with monoclonal antibodies against oncogene antigens
JP3040121B2 (ja) *	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en)	1988-01-12	1998-02-24	Genentech, Inc.	In vivo tumor detection assay
EP0412116B1 (fr)	1988-04-18	1995-11-29	Oncogene Science, Inc.	Detection d'expression de genes neu et produits
JP2761543B2 (ja)	1988-08-17	1998-06-04	味の素株式会社	ヒト癌原遺伝子産物に対するモノクローナル抗体及びそれを産生するハイブリドーマ
ATE155813T1 (de)	1989-05-19	1997-08-15	Genentech Inc	Her2 extrazellulare domäne
US5705157A (en)	1989-07-27	1998-01-06	The Trustees Of The University Of Pennsylvania	Methods of treating cancerous cells with anti-receptor antibodies
US6884418B1 (en)	1989-08-04	2005-04-26	Berlex Laboratories, Inc.	Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
ATE207958T1 (de)	1989-08-04	2001-11-15	Schering Ag	Äusserliche domäne von c-erbb-2:gp75
JP2895105B2 (ja)	1989-09-14	1999-05-24	株式会社ニチレイ	ｃ‐ｅｒｂＢ‐２癌遺伝子産物をイムノアッセイする乳癌の血清診断法とそのキット
WO1991005264A1 (fr)	1989-09-29	1991-04-18	Oncogenetics Partners	Detection et quantification des proteines apparentees neu dans les liquides biologiques des humains
US5183884A (en)	1989-12-01	1993-02-02	United States Of America	Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5464751A (en)	1990-04-06	1995-11-07	Trustees Of The University Of Pennsylvania	Ligand for the neu gene product
US5578482A (en)	1990-05-25	1996-11-26	Georgetown University	Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
AU643109B2 (en)	1990-12-14	1993-11-04	Cell Genesys, Inc.	Chimeric chains for receptor-associated signal transduction pathways
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
US5367060A (en)	1991-05-24	1994-11-22	Genentech, Inc.	Structure, production and use of heregulin
US5834229A (en)	1991-05-24	1998-11-10	Genentech, Inc.	Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943A0 (en)	1991-05-24	1992-12-30	Genentech Inc	Structure,production and use of heregulin
WO1994004679A1 (fr)	1991-06-14	1994-03-03	Genentech, Inc.	Procede pour fabriquer des anticorps humanises
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
US5939531A (en)	1991-07-15	1999-08-17	Novartis Corp.	Recombinant antibodies specific for a growth factor receptor
EP0554441B1 (fr)	1991-08-22	1999-01-27	Becton, Dickinson and Company	Procedes et compositions de traitements de cancers et de pronostic de reactions auxdits traitements
US5288477A (en)	1991-09-27	1994-02-22	Becton, Dickinson And Company	Method for prognosticating response to cancer therapy
FI941572L (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993012220A1 (fr)	1991-12-12	1993-06-24	Berlex Laboratories, Inc.	ANTICORPS DE RECOMBINAISON ET CHIMERIQUES CONTRE c-erbB-2
ATE295420T1 (de)	1992-02-06	2005-05-15	Chiron Corp	Marker für krebs und biosynthetisches bindeprotein dafür
US5660827A (en)	1992-03-05	1997-08-26	Board Of Regents, The University Of Texas System	Antibodies that bind to endoglin
AU4025193A (en)	1992-04-08	1993-11-18	Cetus Oncology Corporation	Humanized C-erbB-2 specific antibodies
ZA932522B (en)	1992-04-10	1993-12-20	Res Dev Foundation	Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
IT1257898B (it) *	1992-06-16	1996-02-16		Procedimento ed apparecchiatura per la produzione, in particolare domestica, di bevande.
JPH08504172A (ja)	1992-06-30	1996-05-07	オンコロジクス，インコーポレイティド	抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
AU5355594A (en)	1992-10-09	1994-05-09	Oncor, Inc.	Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue
FR2697752B1 (fr)	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
CA2103323A1 (fr)	1992-11-24	1994-05-25	Gregory D. Plowman	Tyrosine kinase du recepteur her4 humain
US5869445A (en)	1993-03-17	1999-02-09	University Of Washington	Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en)	1993-03-17	1998-09-01	University Of Washington	Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
ES2141128T3 (es)	1993-03-24	2000-03-16	Berlex Biosciences	Combinacion de agentes anti-hormonales y moleculas de fijacion.
WO1994022478A1 (fr)	1993-03-30	1994-10-13	The Trustees Of The University Of Pennsylvania	PREVENTION DE TUMEURS AVEC DES ANTICORPS MONOCLONAUX DIRIGES CONTRE L'ONCOGENE $i(NEU)
US5430620A (en)	1993-10-08	1995-07-04	Cogent Light Technologies, Inc.	Compact surgical illumination system capable of dynamically adjusting the resulting field of illumination
US6811779B2 (en)	1994-02-10	2004-11-02	Imclone Systems Incorporated	Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US20030108545A1 (en)	1994-02-10	2003-06-12	Patricia Rockwell	Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US5837523A (en)	1994-05-05	1998-11-17	The Trustees Of The University Of Pennsylvania	Compositions and methods of treating tumors
US5910486A (en)	1994-09-06	1999-06-08	Uab Research Foundation	Methods for modulating protein function in cells using, intracellular antibody homologues
US5846749A (en)	1994-10-12	1998-12-08	The Regents Of The University Of California	Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5804396A (en)	1994-10-12	1998-09-08	Sugen, Inc.	Assay for agents active in proliferative disorders
US6214388B1 (en) *	1994-11-09	2001-04-10	The Regents Of The University Of California	Immunoliposomes that optimize internalization into target cells
EP0711565B1 (fr)	1994-11-10	1998-08-26	Eberhard-Karls-Universität Tübingen Universitätsklinikum	Inhibition de la croissance des cellules leucemiques par ciblage de la protéine HER-2
WO1996016673A1 (fr)	1994-12-02	1996-06-06	Chiron Corporation	Methode permettant d'induire une reponse immunitaire avec un anticorps bispecifique
US5783404A (en)	1995-04-13	1998-07-21	Amgen Inc.	Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US5663144A (en)	1995-05-03	1997-09-02	The Trustees Of The University Of Pennsylvania	Compounds that bind to p185 and methods of using the same
DE69629291T2 (de) *	1995-05-26	2004-04-22	Igen International, Inc.(n.d.Ges.d.Staates Delaware)	Molekular geprägten perl polymere und stabilisierte suspensionspolymerisation von diesen in perfluorkohlstoff flussigkeiten
JP3354035B2 (ja) *	1995-05-31	2002-12-09	富士写真フイルム株式会社	ハロゲン化銀カラー写真感光材料の処理方法
US6410690B1 (en)	1995-06-07	2002-06-25	Medarex, Inc.	Therapeutic compounds comprised of anti-Fc receptor antibodies
CA2245835A1 (fr)	1995-06-14	1997-01-03	The Regents Of The University Of California	Nouveaux anticorps humains a forte affinite diriges contre des antigenes tumoraux
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US5783186A (en) *	1995-12-05	1998-07-21	Amgen Inc.	Antibody-induced apoptosis
JP2001505529A (ja)	1996-03-20	2001-04-24	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	Ｈｅｒ―２／ｎｅｕを過剰発現する癌細胞の化学療法への感作
US5925519A (en)	1996-06-03	1999-07-20	The Regents Of The University Of California	Genetic alterations associated with prostate cancer
US5922845A (en)	1996-07-11	1999-07-13	Medarex, Inc.	Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
KR20060079258A (ko)	1996-10-18	2006-07-05	제넨테크, 인크.	항-ＥｒｂＢ２ 항체
AU5243198A (en)	1996-10-30	1998-05-22	Uab Research Foundation, The	Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
AU737910B2 (en)	1997-01-31	2001-09-06	Regents Of The University Of California, The	Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US5994071A (en)	1997-04-04	1999-11-30	Albany Medical College	Assessment of prostate cancer
ZA9811162B (en) *	1997-12-12	2000-06-07	Genentech Inc	Treatment with anti-ERBB2 antibodies.
EP1064027B1 (fr)	1998-03-27	2008-06-18	Genentech, Inc.	Synergie des anticorps anti-her-2 et des ligands pour l'apo-2
CN1305896C (zh)	1998-05-06	2007-03-21	基因技术股份有限公司	用离子交换层析纯化蛋白质
US6316462B1 (en)	1999-04-09	2001-11-13	Schering Corporation	Methods of inducing cancer cell death and tumor regression
US6333348B1 (en)	1999-04-09	2001-12-25	Aventis Pharma S.A.	Use of docetaxel for treating cancers
SI1187632T1 (sl)	1999-05-14	2009-04-30	Genentech Inc	Zdravljenje z anti-ErbB2 protitelesi
EP1189634B1 (fr)	1999-06-25	2007-02-28	Genentech, Inc.	Traitement du cancer de la prostate a l'aide des anticorps anti-erbb2
US7041292B1 (en)	1999-06-25	2006-05-09	Genentech, Inc.	Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en)	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US6949245B1 (en)	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en)	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
DE60042693D1 (de) *	1999-08-27	2009-09-17	Genentech Inc	Dosierung für die behandlung mit anti erbb2-antikörpern
US7097840B2 (en)	2000-03-16	2006-08-29	Genentech, Inc.	Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
IL152389A0 (en)	2000-05-15	2003-05-29	Pharmacia Italia Spa	Aromatase inhibitors and monoclonal anti-her1 antibodies as antitumor agents
NZ522444A (en)	2000-05-19	2004-09-24	Genentech Inc	Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
AU2002239486A1 (en)	2000-12-08	2002-06-18	Uab Research Foundation	Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
WO2002055106A2 (fr)	2001-01-09	2002-07-18	Merck Patent Gmbh	Polytherapie faisant appel a des inhibiteurs de recepteurs tyrosine kinase et a des inhibiteurs d'angiogenese
ES2376165T3 (es)	2002-07-15	2012-03-09	F. Hoffmann-La Roche Ag	Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
WO2004048525A2 (fr)	2002-11-21	2004-06-10	Genentech, Inc.	Therapie de maladies ou troubles benins a l'aide d'anticorps anti-erbb2
JP4969440B2 (ja)	2004-04-08	2012-07-04	デビッド，ビー．エイガス，	疼痛治療のためのＥｒｂＢアンタゴニスト
GT200500155A (es)	2004-06-16	2006-05-15		Terapia del càncer resistente al platino
HRP20141111T1 (hr)	2004-07-22	2015-01-02	Genentech, Inc.	Sastav her2-protutijela
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
KR20070085855A (ko)	2004-12-07	2007-08-27	제넨테크, 인크.	Ｈｅｒ 억제제를 이용한 치료를 위한 환자 선택 방법
BRPI0518104B8 (pt)	2005-01-21	2021-05-25	Genentech Inc	artigo industrializado e uso de anticorpo her2
RU2404806C2 (ru)	2005-02-23	2010-11-27	Дженентек, Инк.	Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
TW200642695A (en)	2005-03-08	2006-12-16	Genentech Inc	Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
JP2006316040A (ja) *	2005-05-13	2006-11-24	Genentech Inc	Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es)	2005-07-22	2007-03-09	Genentech Inc	Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en)	2005-08-12	2010-04-20	Hoffmann-La Roche Inc.	Method for predicting the response to a treatment
TW200812615A (en)	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CA2654584A1 (fr)	2006-06-05	2007-12-21	Genentech, Inc.	Prolongation de la survie de patients cancereux presentant des niveaux eleves d'egf ou de tgf-alpha
JP5317084B2 (ja)	2006-11-08	2013-10-16	国立大学法人愛媛大学	π共役環状化合物およびその製造方法
CA2677108A1 (fr) *	2007-03-02	2008-09-12	Genentech, Inc.	Element de prevision de la reponse a un inhibiteur de her
JP5117165B2 (ja)	2007-11-09	2013-01-09	花王株式会社	水中油型乳化組成物の製造方法
JP5170667B2 (ja)	2008-06-02	2013-03-27	小林クリエイト株式会社	情報隠蔽帳票
BRPI0812682A2 (pt) *	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
JP5213775B2 (ja)	2009-03-25	2013-06-19	株式会社ジャパンディスプレイウェスト	電気光学装置および電子機器

1998
- 1998-12-07 ZA ZA9811162A patent/ZA9811162B/xx unknown
- 1998-12-10 TR TR2000/01689T patent/TR200001689T2/xx unknown
- 1998-12-10 KR KR1020007006372A patent/KR20010033019A/ko not_active Ceased
- 1998-12-10 US US09/208,649 patent/US7846441B1/en not_active Expired - Fee Related
- 1998-12-10 EP EP10177992A patent/EP2275450A1/fr not_active Withdrawn
- 1998-12-10 AU AU19081/99A patent/AU1908199A/en not_active Abandoned
- 1998-12-10 BR BR9815363-3A patent/BR9815363A/pt not_active Application Discontinuation
- 1998-12-10 KR KR1020087018921A patent/KR20080075042A/ko not_active Ceased
- 1998-12-10 IL IL13620198A patent/IL136201A0/xx unknown
- 1998-12-10 CA CA2730373A patent/CA2730373A1/fr not_active Abandoned
- 1998-12-10 EP EP98963840.8A patent/EP1037926B1/fr not_active Revoked
- 1998-12-10 WO PCT/US1998/026266 patent/WO1999031140A1/fr not_active Ceased
- 1998-12-10 KR KR1020137005286A patent/KR20130036367A/ko not_active Ceased
- 1998-12-10 CN CNB988120976A patent/CN1269839C/zh not_active Expired - Lifetime
- 1998-12-10 CN CN200610008639XA patent/CN1820734B/zh not_active Ceased
- 1998-12-10 CA CA2311409A patent/CA2311409C/fr not_active Expired - Lifetime
- 1998-12-10 JP JP2000539062A patent/JP2002508397A/ja not_active Withdrawn
- 1998-12-10 KR KR1020147035850A patent/KR20150013870A/ko not_active Ceased
- 1998-12-10 ES ES98963840.8T patent/ES2450922T3/es not_active Expired - Lifetime
- 1998-12-10 KR KR1020127013045A patent/KR20120062942A/ko not_active Withdrawn
- 1998-12-10 EP EP10178009A patent/EP2277919A1/fr not_active Ceased
- 1998-12-10 DK DK98963840.8T patent/DK1037926T3/da active
- 1998-12-10 KR KR1020187027274A patent/KR20180107323A/ko not_active Ceased
- 1998-12-10 KR KR1020107028433A patent/KR20100135337A/ko not_active Ceased
- 1998-12-11 AR ARP980106308A patent/AR020051A1/es unknown
2000
- 2000-05-17 IL IL136201A patent/IL136201A/en not_active IP Right Cessation
- 2000-05-17 NZ NZ504597A patent/NZ504597A/en not_active IP Right Cessation
- 2000-06-09 NO NO20002957A patent/NO20002957L/no unknown
2003
- 2003-02-03 US US10/356,824 patent/US7892549B2/en not_active Expired - Fee Related
- 2003-04-04 US US10/406,925 patent/US20030170234A1/en not_active Abandoned
2004
- 2004-08-02 US US10/909,998 patent/US8642036B2/en not_active Expired - Lifetime
2007
- 2007-07-20 US US11/780,640 patent/US8075892B2/en not_active Expired - Fee Related
2008
- 2008-01-04 US US11/969,465 patent/US20080187533A1/en not_active Abandoned
2009
- 2009-03-17 NO NO20091147A patent/NO20091147L/no not_active Application Discontinuation
2010
- 2010-04-07 JP JP2010088515A patent/JP2010209081A/ja active Pending
2011
- 2011-05-09 US US13/103,799 patent/US8309087B2/en not_active Expired - Fee Related
- 2011-07-14 IL IL214084A patent/IL214084A/en not_active IP Right Cessation
- 2011-07-18 US US13/185,329 patent/US8425908B2/en not_active Expired - Fee Related
2012
- 2012-10-04 JP JP2012222108A patent/JP2013056887A/ja not_active Withdrawn
2013
- 2013-03-15 US US13/841,146 patent/US20130209459A1/en not_active Abandoned
- 2013-12-26 US US14/141,232 patent/US20140341886A1/en not_active Abandoned
2014
- 2014-09-17 IL IL234696A patent/IL234696A/en not_active IP Right Cessation
2015
- 2015-06-09 JP JP2015116874A patent/JP2016006046A/ja not_active Withdrawn
2016
- 2016-09-23 JP JP2016185281A patent/JP2017039737A/ja active Pending
2017
- 2017-04-05 JP JP2017075241A patent/JP2017165737A/ja not_active Withdrawn
2018
- 2018-12-05 JP JP2018227941A patent/JP2019055979A/ja active Pending
2019
- 2019-04-23 US US16/392,300 patent/US20190240185A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2002508397A (ja)	2002-03-19
EP1037926B1 (fr)	2014-01-15
EP1037926A1 (fr)	2000-09-27
JP2010209081A (ja)	2010-09-24
US8425908B2 (en)	2013-04-23
HK1091391A1 (en)	2007-01-19
US20070292419A1 (en)	2007-12-20
IL214084A (en)	2015-02-26
CA2730373A1 (fr)	1999-06-24
CN1820734B (zh)	2011-06-15
ES2450922T3 (es)	2014-03-25
AR020051A1 (es)	2002-04-10
US20120034213A1 (en)	2012-02-09
US20080187533A1 (en)	2008-08-07
US7892549B2 (en)	2011-02-22
CN1281468A (zh)	2001-01-24
JP2016006046A (ja)	2016-01-14
US20140341886A1 (en)	2014-11-20
US20030170234A1 (en)	2003-09-11
BR9815363A (pt)	2001-10-16
IL136201A (en)	2011-08-31
KR20080075042A (ko)	2008-08-13
US7846441B1 (en)	2010-12-07
KR20010033019A (ko)	2001-04-25
CA2311409A1 (fr)	1999-06-24
KR20180107323A (ko)	2018-10-01
KR20150013870A (ko)	2015-02-05
KR20100135337A (ko)	2010-12-24
EP2275450A1 (fr)	2011-01-19
US20040037823A9 (en)	2004-02-26
TR200001689T2 (tr)	2001-01-22
JP2017039737A (ja)	2017-02-23
CN1269839C (zh)	2006-08-16
IL214084A0 (en)	2011-08-31
JP2019055979A (ja)	2019-04-11
US8309087B2 (en)	2012-11-13
US20030147884A1 (en)	2003-08-07
JP2013056887A (ja)	2013-03-28
DK1037926T3 (en)	2014-03-03
IL136201A0 (en)	2001-05-20
ZA9811162B (en)	2000-06-07
KR20130036367A (ko)	2013-04-11
US20050002928A1 (en)	2005-01-06
CN1820734A (zh)	2006-08-23
JP2017165737A (ja)	2017-09-21
NZ504597A (en)	2003-05-30
HK1030784A1 (en)	2001-05-18
AU1908199A (en)	1999-07-05
US20190240185A1 (en)	2019-08-08
IL234696A (en)	2017-06-29
CA2311409C (fr)	2011-04-12
NO20091147L (no)	2000-08-11
US20130209459A1 (en)	2013-08-15
US8075892B2 (en)	2011-12-13
NO20002957D0 (no)	2000-06-09
KR20120062942A (ko)	2012-06-14
US20110250194A1 (en)	2011-10-13
US8642036B2 (en)	2014-02-04
WO1999031140A1 (fr)	1999-06-24
EP2277919A1 (fr)	2011-01-26

Publication	Publication Date	Title
NO20002957L (no)	2000-08-11	Behandling med anti-ErbB2-antistoffer
DK1189641T3 (da)	2009-11-16	Humaniserede ANTI-ErbB2-antistoffer og behandling med ANTI-ErbB2-antistoffer
DE69729672D1 (de)	2004-08-05	Biosensor
DE69935516D1 (de)	2007-04-26	Antikörper mit verbesserter produzierbarkeit
CY2005008I1 (el)	2009-11-04	Αντισωματα αντι - vegf
FI970468A0 (fi)	1997-02-04	Anvaendningspraoksberoende bokstavsmatning med nummertangenter
FI952093A0 (fi)	1995-05-02	Kapsling foer med akustiska ytvaogefunktionerande byggelement
FI951568A7 (fi)	1995-10-08	Immobilisoitu beta-mannaasi
FI974269A0 (fi)	1997-11-18	Radiosaendare-mottagarestruktur med tvao frekvensomraoden
FI972664A0 (fi)	1997-06-19	Foerseglad saeck med avluftning
FR2765954B3 (fr)	1999-07-23	Radiant
DK1019042T3 (da)	2003-08-25	Forbindelser med anti-første-passagevirkning
FI974544A0 (fi)	1997-12-17	Anordning i en med manoeverplats foersedd lastkran
FI970405A0 (fi)	1997-01-31	Plattformad traeprodukt med skiktstruktur
FI970017A0 (fi)	1997-01-03	Med lampeffekts maetning foersett reglerbart elektroniskt anslutningsorgan
FI970870A0 (fi)	1997-02-28	Tvaettlapp med oerter
FI974642A0 (fi)	1997-12-30	Arbetsbord med tvaettho
FI973903A0 (fi)	1997-10-07	Rundbalshack med cylindrisk behaollarew
FI973862A0 (fi)	1997-10-02	Isborr med fasningsskaer
FI973598A0 (fi)	1997-09-04	Lastutrymme med utskjutbart golv
FI970473A0 (fi)	1997-02-04	Vaextextraktblandning med antiherpasaktivitet
FI972507A0 (fi)	1997-06-13	Graesklippningssax med skaft
FI972274A0 (fi)	1997-05-29	Foerfarande foer roekgasrening med snabba elektroner
FI971819A0 (fi)	1997-04-29	Borste med stoed
FI974641A0 (fi)	1997-12-30	SOP-/torkanordning med loestagbart skaft